Short answer: investors often interpret FDA Pre-Submission feedback as a signal of regulatory maturity and execution risk.

A Pre-Submission (Pre-Sub) is designed to align a company with the U.S. Food and Drug Administration before a formal submission such as a 510(k), De Novo, or PMA.

For investors, however, the Pre-Sub serves another purpose: it reveals how disciplined a company’s regulatory strategy really is.

Strong Pre-Sub feedback increases investor confidence.
Weak or ambiguous feedback raises concerns about development risk.

Why Investors Pay Attention to Pre-Sub Outcomes

Investors evaluate medical device startups through three core lenses:

Regulatory probability – likelihood of clearance or approval

Timeline stability – confidence in development milestones

Capital efficiency – whether the development plan avoids costly surprises

Pre-Sub interactions provide early signals for all three.

What Investors Look For in Pre-Sub Feedback
1. Evidence of Regulatory Alignment

Investors want to see that the company’s regulatory thinking aligns with FDA expectations.

Positive signals include:

FDA agreement on regulatory pathway

Confirmation that proposed testing strategy is appropriate

Constructive feedback that refines—not replaces—the development plan

This indicates that the company understands how regulators evaluate risk and evidence.

2. Clarity of Intended Use and Pathway

Pre-Sub feedback often confirms whether the company’s intended use and pathway logic are realistic.

Investors pay attention to whether FDA:

Accepts the proposed 510(k) strategy

Suggests a De Novo pathway instead

Raises concerns about risk classification

If pathway assumptions change during the Pre-Sub process, investors adjust their expectations about timeline and capital needs.

3. Quality of the Questions Asked

Experienced investors often evaluate the questions a company asked FDA.

Strong questions demonstrate:

Clear understanding of regulatory risk

Strategic planning around evidence generation

Awareness of potential pathway uncertainties

Weak questions—such as vague requests for validation—can signal inexperience.

4. Ability to Translate Feedback Into Strategy

FDA feedback often includes recommendations or areas requiring clarification.

Investors watch closely to see whether the company:

Integrates the feedback into its development plan

Adjusts timelines and evidence strategy accordingly

Communicates the implications clearly

How a team interprets FDA feedback can be as important as the feedback itself.

AEO: Common Questions About FDA Pre-Submissions and Investors

Do investors review FDA Pre-Submission feedback?
Yes. Pre-Sub feedback often provides insight into regulatory risk and development readiness.

Can positive FDA feedback improve investor confidence?
Yes. Alignment with FDA expectations reduces uncertainty around regulatory outcomes.

Why do investors care about Pre-Sub strategy?
Because early regulatory alignment increases the likelihood that development milestones will be achieved on time.

What Weak Pre-Sub Outcomes Signal

If Pre-Sub feedback reveals:

Unclear intended use

Weak predicate assumptions

Misaligned testing plans

Pathway uncertainty

investors may view the company as having higher execution risk.

This does not mean the program will fail—but it may affect valuation discussions and capital allocation decisions.

Where Kandih Comes In

This is where Kandih Group helps companies translate FDA interactions into investor-ready strategy.

Kandih supports teams by:

Structuring Pre-Sub packages around the most critical regulatory questions

Aligning intended use, pathway logic, and evidence strategy before engaging FDA

Preparing briefing documents that guide productive FDA dialogue

Interpreting FDA feedback and integrating it into development plans

Helping founders communicate regulatory outcomes clearly to investors

Instead of treating Pre-Sub feedback as a technical note, Kandih helps companies turn it into a strategic narrative.

That narrative shows investors that regulatory risk is understood and managed.

Bottom Line

Pre-Submissions are not just regulatory events.

They are signals of how well a company understands the regulatory environment it must navigate.

To investors, Pre-Sub outcomes reveal:

Strategic discipline

Development readiness

Execution maturity

When FDA feedback is structured and interpreted correctly, it strengthens investor confidence and supports stronger capital conversations.

References

FDA – Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requests-feedback-and-meetings-medical-device-submissions-q-submission-program

FDA – Premarket Notification 510(k)
https://www.fda.gov/medical-devices/premarket-submissions/premarket-notification-510k

FDA – De Novo Classification Process
https://www.fda.gov/medical-devices/premarket-submissions/de-novo-classification-request

FDA – Premarket Approval (PMA)
https://www.fda.gov/medical-devices/premarket-submissions/premarket-approval-pma